<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">KLK1 Gene</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td>KLK1</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Kallikrein Related Peptidase 1</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>19q13.33</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>3756</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>147910</td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td>ENSG00000167748</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td>P06858</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/atherosclerosis" style="color:#ef9a9a">Atherosclerosis</a>, <a href="/wiki/inflammation" style="color:#ef9a9a">Inflammation</a>, <a href="/wiki/neuroinflammation" style="color:#ef9a9a">Neuroinflammation</a>, <a href="/wiki/stroke" style="color:#ef9a9a">Stroke</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">15 edges</a></td>
</tr>
</table>
KLK1 (Kallikrein-Related Peptidase 1) encodes a serine protease that belongs to the human kallikrein gene family, the largest cluster of protease genes in the human genome. The KLK1 protein, also known as tissue kallikrein, is a 262-amino acid glycoprotein that catalyzes the hydrolysis of kininogen to produce bradykinin, a potent vasoactive peptide involved in inflammation, blood pressure regulation, and tissue remodeling. While traditionally studied in the context of cardiovascular function and inflammation, emerging evidence suggests KLK1 plays important roles in the central nervous system, where it influences neuroinflammation, neuronal survival, and neurodegenerative disease pathogenesis. [@matsumoto2020]
The KLK gene cluster on chromosome 19q13.33 contains 15 kallikrein genes (KLK1-KLK15) encoding serine proteases with diverse physiological functions. KLK1 is expressed in various tissues, including brain, where it is produced by neurons and glial cells. The enzyme's activity is regulated by protease inhibitors, including serpins and alpha-1 antitrypsin, ensuring precise control of kinin generation and downstream signaling. [@bickel1995]
KLK1 contains the typical serine protease fold:
Signal Peptide: A 16-amino acid N-terminal signal peptide directs secretion via the classical secretory pathway.
Activation Peptide: A short activation peptide that is cleaved to activate the zymogen form.
Protease Domain: The catalytic domain contains the characteristic serine protease active site with the catalytic triad (His57, Asp102, Ser195 in chymotrypsin numbering).
C-terminal Fragment: The remainder of the protein forms the substrate-binding pocket that determines substrate specificity.
KLK1 performs several key functions:
Kinin Generation: KLK1 specifically cleaves low-molecular-weight kininogen (LMWK) to release bradykinin (Lys-bradykinin, kallidin). This enzymatic activity is the most well-characterized function of KLK1. [@scicinski1993]
Bradykinin Signaling: Through the B1 and B2 bradykinin receptors (BDKRB1, BDKRB2), bradykinin triggers multiple downstream signaling pathways, including:
KLK1 involvement in AD manifests through multiple mechanisms:
Neuroinflammation: Bradykinin signaling via B2 receptors can promote neuroinflammation through NF-κB activation and cytokine release. Chronic neuroinflammation is a hallmark of AD pathogenesis. [@wohlers2013]
Amyloid Processing: KLK1 can potentially influence amyloid precursor protein (APP) processing and amyloid-beta generation. Studies in cell models suggest KLK1 may affect amyloidogenic processing pathways.
Blood-Brain Barrier: Bradykinin increases blood-brain barrier permeability, potentially affecting Aβ clearance and immune cell infiltration.
Neuronal Function: KLK1 is expressed in neurons, where it may participate in synaptic function and plasticity. Altered expression may contribute to synaptic dysfunction in AD. [@bond2018]
In Parkinson's disease, KLK1 connects to disease mechanisms through:
Dopaminergic Neurons: KLK1 expression is altered in PD brains. The enzyme may influence dopaminergic neuron survival through modulation of inflammatory pathways and protein processing.
Alpha-Synuclein Processing: KLK1 may interact with alpha-synuclein aggregation pathways. Proteolytic processing of α-syn by kallikreins could influence aggregation propensity.
Neuroinflammation: As in AD, bradykinin-mediated inflammation contributes to PD pathogenesis. The substantia nigra shows particular vulnerability to inflammatory insults. [@kishikawa2019]
KLK1 may contribute to ALS through:
Motor Neuron Vulnerability: KLK1 expression in motor neurons and surrounding glial cells may influence inflammatory processes that contribute to motor neuron degeneration.
Protein Aggregate Processing: KLK1's proteolytic activity may intersect with protein aggregate clearance pathways relevant to ALS pathogenesis.
A common theme in KLK1's neurodegenerative effects is modulation of neuroinflammation:
Microglial Activation: Bradykinin can activate microglial cells, promoting pro-inflammatory cytokine production (IL-1β, TNF-α, IL-6).
Peripheral Immune Recruitment: Through BBB modulation, KLK1 may facilitate peripheral immune cell entry into the CNS.
Chronic Inflammation: Persistent KLK1 activation may contribute to chronic neuroinflammatory states that drive neurodegeneration. [@ramachandran2011]
The kallikrein-kinin system represents a therapeutic target:
Kallikrein Inhibitors: Small molecule inhibitors of KLK1 could reduce bradykinin production and associated neuroinflammation. However, systemic effects may cause adverse reactions.
Bradykinin Receptor Antagonists: B1 and B2 receptor antagonists might block downstream signaling without affecting KLK1 activity directly. The B2 receptor is constitutively active, while B1 is induced under inflammatory conditions.
Gene Expression Modulation: Approaches to reduce KLK1 expression in the CNS could provide benefit, though delivery challenges exist.
BBB Penetration: CNS-targeted delivery is essential for neurological applications. Prodrug approaches or intranasal administration may improve brain penetration.
Peripheral Effects: Systemic KLK1 inhibition may affect cardiovascular function, requiring careful dosing and monitoring.
Combination Approaches: KLK1 targeting may complement other therapeutic strategies in neurodegenerative diseases. [@williams2021]
The following diagram shows the key molecular relationships involving KLK1 Gene discovered through SciDEX knowledge graph analysis: